Skip to content
10-Q

Quarterly Report

BioCrude Technologies USA, Inc.

0001731122-24-000756

← back to feed
Filed
May 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 8, 2024 50.85M sh
Capex Q1 2024 · Mar 31, 2024 $0
Capex Q1 2024 · Mar 31, 2023 $0
Short Term Debt Q1 2024 · Mar 31, 2024 $132.86K
Short Term Debt Q1 2024 · Dec 31, 2023 $133.97K
Stockholders Equity Q1 2024 · Mar 31, 2024 −$255.4K
Stockholders Equity Q1 2024 · Dec 31, 2023 −$234.08K
Current Liabilities Q1 2024 · Mar 31, 2024 $291.29K
Current Liabilities Q1 2024 · Dec 31, 2023 $253.99K
Total Liabilities Q1 2024 · Mar 31, 2024 $291.29K
Total Liabilities Q1 2024 · Dec 31, 2023 $253.99K
Current Assets Q1 2024 · Mar 31, 2024 $17.08K
Current Assets Q1 2024 · Dec 31, 2023 $0
Total Assets Q1 2024 · Mar 31, 2024 $31.93K
Total Assets Q1 2024 · Dec 31, 2023 $15.93K
Shares Diluted Q1 2024 · Mar 31, 2023 50.75M sh
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$15.03K
Eps Diluted Q1 2024 · Mar 31, 2023 $0.00
Eps Basic Q1 2024 · Mar 31, 2023 $0.00
Sga Expense Q1 2024 · Mar 31, 2023 $61.46K
Net Income Q1 2024 · Mar 31, 2023 −$62.39K
Operating Income Q1 2024 · Mar 31, 2023 −$61.46K